Claims
- 1. A sealant composition comprising a polymerized collagen type III wherein said sealant composition is produced by recombinantly manufacturing pure collagen type III monomers in a cell and polymerizing said monomers with an agent.
- 2. The composition of claim 1, wherein the composition is biologically compatible.
- 3. The composition of claim 1, wherein the recombinant manufacture of a collagen type III monomer comprises the following steps:
(a) culturing a cell which has been transfected with at least one gene encoding a polypeptide comprising collagen type III and at least one gene encoding a polypeptide selected from the group the α or β subunit of prolyl 4-hydroxylase; and (b) purifying said collagen type III.
- 4. The composition of claim 1, wherein the composition is further comprised of one or more agents selected from the group fibrin, fibrinogen, thrombin, Factor XIII, or connective tissue growth factor.
- 5. The composition of claim 1, wherein the sealant is a vascular sealant.
- 6. The composition of claim 1, wherein the collagen is gelatin.
- 7. The composition of claim 1, wherein the composition is non-adhesive.
- 8. The composition of claim 7, wherein the composition is further comprised of albumin.
- 9. The composition of claim 1, wherein the polymerizing is accomplished by cross-linking.
- 10. A process for making a tissue sealant comprising the steps:
(a) manufacturing collagen type III monomers by recombinant means; and (b) polymerizing said collagen type III monomers.
- 11. The process of claim 10, wherein the polymerizing is accomplished by cross-linking.
- 12. A sealant composition comprising a polymerized collagen type I wherein said sealant composition is produced by recombinantly manufacturing pure collagen type I monomers in a cell and polymerizing said monomers with an agent.
- 13. The composition of claim 12, wherein the composition is biologically compatible.
- 14. The composition of claim 12, wherein the recombinant manufacture of a collagen type I monomer comprises the following steps:
(a) culturing a cell which has been transfected with at least one gene encoding a polypeptide comprising collagen type I and at least one gene encoding a polypeptide selected from the group the α or β subunit of prolyl 4-hydroxylase; and (b) purifying said collagen type I.
- 15. The composition of claim 12, wherein the collagen is a gelatin.
- 16. The composition of claim 12, wherein the composition is further comprised of one or more agents selected from the group fibrin, fibrinogen, thrombin, Factor XIII or connective tissue growth factor.
- 17. The composition of claim 12, wherein the sealant is a vascular sealant.
- 18. The composition of claim 12, wherein the collagen type I is a heterotrimer collagen.
- 19. The composition of claim 12, wherein the collagen type I is a homotrimer collagen.
- 20. The composition of claim 12, wherein the composition is non-adhesive.
- 21. The composition of claim 20, wherein the composition is further comprised of albumin.
- 22. The composition of claim 12, wherein the polymerizing is accomplished by cross-linking.
- 23. A process for making a tissue sealant comprising the steps:
(a) manufacturing collagen type I monomers by recombinant means; and (b) polymerizing said collagen type I monomers.
- 24. The process of claim 23, wherein the polymerizing is accomplished by cross-linking.
- 25. A tissue sealant composition comprising a polymerized pure collagen type III and a polymerized pure collagen type I.
- 26. The composition of claim 25 wherein the composition is biologically compatible.
- 27. The composition of claim 25 wherein the ratio of pure recombinant collagen type III to pure recombinant collagen type I is about 30% or greater collagen type III to about 70% or less collagen type I.
- 28. The composition of claim 25 wherein the collagen is a gelatin.
- 29. The composition of claim 25 wherein the composition is further comprised of one or more agents selected from the group fibrin, fibrinogen, thrombin, Factor XIII or connective tissue growth factor.
- 30. A wound dressing composition comprising a polymerized collagen type III wherein said composition is produced by recombinantly manufacturing pure collagen type III monomers in a cell and polymerizing said monomers with an agent.
- 31. The composition of claim 30 wherein the composition is biologically compatible.
- 32. The composition of claim 30 wherein the recombinant manufacture of a collagen type III monomer comprises the following steps:
(a) culturing a cell which has been transfected with at least one gene encoding a polypeptide comprising collagen type III and at least one gene encoding a polypeptide selected from the group the α or β subunit of prolyl 4-hydroxylase; and (b) purifying said collagen type III.
- 33. The composition of claim 30, wherein said collagens are a gelatin.
- 34. The composition of claim 30, wherein the composition is further comprised of one or more agents selected from the group fibrin, fibrinogen, thrombin, Factor XIII or connective tissue growth factor.
- 35. The compostion of claim 30, wherein the polymerizing is accomplished by cross-linking.
- 36. A process for making a wound dressing comprising the steps:
(a) manufacturing collagen type III monomers by recombinant means; and (b) polymerizing said collagen type III monomers.
- 37. The process of claim 36, wherein the polymerizing is accomplished by cross-linking.
- 38. A wound dressing composition comprising a polymerized collagen type I wherein said composition is produced by recombinantly manufacturing pure collagen type I monomers in a cell and polymerizing said monomers with an agent.
- 39. The composition of claim 38 wherein the composition is biologically compatible
- 40. The composition of claim 38 wherein the recombinant manufacture of a collagen type I monomer comprises the following steps:
(a) culturing a cell which has been transfected with at least one gene encoding a polypeptide comprising collagen type I and at least one gene encoding a polypeptide selected from the group the α or β subunit of prolyl 4-hydroxylase; and (b) purifying said collagen type I.
- 41. The composition of claim 38 wherein the said collagen is a gelatin.
- 42. The composition of claim 38 wherein the composition is further comprised of one or more agents selected from the group fibrin, fibrinogen, thrombin, Factor XIII or connective tissue growth factor.
- 43. The composition of claim 38, wherein the collagen is gelatin.
- 44. The composition of claim 38, wherein the collagen type I is a heterotrimer collagen.
- 45. The composition of claim 38, wherein the collagen type I is a homotrimer collagen.
- 46. The composition of claim 38, wherein the polymerizing is accomplished by cross-linking.
- 47. A process for making a wound dressing comprising the steps:
(a) manufacturing collagen type I monomers by recombinant means; and (b) polymerizing said collagen type I monomers.
- 48. The process of claim 47, wherein the polymerizing is accomplished by cross-linking.
- 49. A wound dressing composition comprising a polymerized pure collagen type III and a polymerized pure collagen type I.
- 50. The composition of claim 49 wherein the composition is biologically compatible.
- 51. The composition of claim 49, wherein the ratio of pure recombinant collagen type III to pure recombinant collagen type I is about 30% or greater collagen type III to about 70% or less collagen type I.
- 52. The composition of claim 49, wherein said collagens are gelatin.
- 53. The composition of claim 49, wherein the composition is further comprised of one or more agents selected from the group fibrin, fibrinogen, thrombin, Factor XIII or connective tissue growth factor.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. application provisional No. 60/095,977
Provisional Applications (1)
|
Number |
Date |
Country |
|
60095977 |
Aug 1998 |
US |